Modern approaches to the treatment of inflammatory bowel disease (IBD) are based on the motto “treat-to-target”, whereby in addition to symptom relief and induction of disease remission, the aim nowadays is also to preserve and endoscopically inconspicuous colon mucosa. New agents from the field of biologics and small molecules, which can be used in cases of inadequate response to conventional drugs, are important sources of hope for optimizing therapeutic outcomes.
Partner
Autoren
- PD Dr. med. Luc Biedermann
Publikation
- HAUSARZT PRAXIS
Related Topics
- 5-ASA
- 6-Mercaptopurine
- Aminosalicylates
- anti-47 integrin
- Anti-inflammatory
- Azathioprine
- biologics
- CED
- chronic inflammatory bowel diseases
- Colonic mucosa
- Crohn's disease
- Cyclosporine A
- IBD matters
- Immunosuppressants
- Methotrexate
- small molecules
- Steroids
- Tacrolimus
- Targets
- TNFα
- Tofacitinib
- Treatment
- Ulcerative colitis
- Ustekinumab
- Vedolizumab
You May Also Like
- Functional gastrointestinal disorders
Menthacarin for irritable bowel syndrome and stomach
- Lymphoma
Treatment goal: slow progression, improve quality of life
- PancNEN, PancNET & PancNEC
Neuroendocrine tumors of the pancreas
- Heart failure
Interventional treatment of the tricuspid valve
- Lipoprotein(a)
Current and future treatment options
- Lichen sclerosus
Topical corticosteroids still the first choice
- Breast Cancer
On the trail of triple-negative breast cancer
- Sleep disorders in old age